Novo Nordisk, Inc. Company Profile

09:25 EDT 23rd August 2014 | BioPortfolio

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


News Articles [322 Associated News Articles listed on BioPortfolio]

Spork leaving Novo as new CEO comes on board

Novo A/S said Ulrik Spork will depart as managing partner of large investments to pursue other opportunities. The move came after the firm determined that Spork's responsibilities could be absorbed by...

Novo Nordisk accepts fine for violating disclosure obligation in Denmark

Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by Novo Nordisk o...

Novo Nordisk to add 6,000 new jobs in Denmark by 2022

Global healthcare company Novo Nordisk expects to hire 6,000 new employees in Denmark through 2022, half of whom will work within R&D. According to a Novo Nordisk report, the new jobs will have the de...

Novo Nordisk aims for 2016 launch of long- acting insulin Tresiba (if FDA will approve it)

COPENHAGEN (Reuters) - Novo Nordisk <NOVOb.CO said on Thursday it could launch its new long-acting insulin Tresiba, a crucial future growth driver for the Danish company, at the start of...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 7 August 2014

BAGSVAERD, Denmark, Aug. 8, 2014 (GLOBE NEWSWIRE) -- In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of a...

Novo Nordisk A/S: Novo Nordisk receives positive opinion on Xultophy(r) (IDegLira) from the European regulatory authorities

Bagsvaerd, Denmark, July 25, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a p...

Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2014

BAGSVAERD, Denmark, April 30, 2014 (GLOBE NEWSWIRE) -- In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total num...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 24 March 2014

Bagsvaerd, Denmark, March 25, 2014 (GLOBE NEWSWIRE) -- In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of...

Drugs and Medications [33 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Physicians Total Care, Inc.]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

R HUMAN Novolin R Regular, Human Insulin Injection (recombinant DNA origin) USP 100 units/mL

PubMed Articles [260 Associated PubMed Articles listed on BioPortfolio]

Response to Hitman. Insulin degludec: a new insulin for today?

It is only natural that people with diabetes, their relatives and their physicians look for genuine therapeutic advance [1]. However, the development and marketing of a novel insulin analogue such as...

De novo Propionibacterium acnes Meningitis in a Patient with Metastatic Melanoma.

Propionibacterium acnes is a known cause of post-neurosurgical meningitis; however, it is rarely implicated in de novo meningitis. Herein we report a case of a 49 year-old male with de novo P. acnes m...

Early postzygotic mutations contribute to de novo variation in a healthy monozygotic twin pair.

Human de novo single-nucleotide variation (SNV) rate is estimated to range between 0.82-1.70×10(-8) mutations per base per generation. However, contribution of early postzygotic mutations to the over...

Cobalamin deficiency triggering de novo status epilepticus.

Cobalamin deficiency is included in the spectrum of very uncommon underlying causes of status epilepticus (SE) and the literature contains very few such cases. We herein report a case of unusual prese...

The clinical impact of switching attention deficit hyperactivity disorder patients from OROS(®)-MPH to Novo-MPH ER-C(®): A paediatric practice review.

In Canada, novo-methylphenidate extended-release capsules (Novo-MPH ER-C, Novopharm Limited, Canada) was approved as being bioequivalent to a current first-line treatment for attention deficit hyperac...

Clinical Trials [204 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemi...

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentra...

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and Nov...

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII) produced by two different manufacturers (N...

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Companies [47 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area...

Novo Nordisk Inc.

More Information about "Novo Nordisk, Inc." on BioPortfolio

We have published hundreds of Novo Nordisk, Inc. news stories on BioPortfolio along with dozens of Novo Nordisk, Inc. Clinical Trials and PubMed Articles about Novo Nordisk, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novo Nordisk, Inc. Companies in our database. You can also find out about relevant Novo Nordisk, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Relevant Topic

Endocrine Disorders
Latest News Clinical Trials Research Drugs Reports Corporate
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record